Prognosis and Survival Outcomes for Pancreatic Head Adenocarcinoma

Overall Survival Statistics

The 5‑year overall survival for pancreatic head adenocarcinoma is less than 10 % and drops to 2 % when the disease is metastatic. 1
Patients with localized disease (≈ 9‑20 % of all cases) have a 5‑year survival of about 26 %. 1
For patients presenting with distant/metastatic disease (≈ 50‑60 % of cases), 1‑year survival is 15 % and 5‑year survival is 2 %. 1
Across all stages, the overall 1‑year survival is 28 % and the overall 5‑year survival is 7 %. 1
Approximately 80‑85 % of patients are diagnosed with advanced, unresectable disease, explaining the poor overall prognosis. 1
More than 95 % of individuals diagnosed with pancreatic head adenocarcinoma eventually die from the disease. 2

Adding adjuvant chemotherapy to surgery increases 5‑year survival to roughly 20 % compared with 9 % for surgery alone. 3
Even in optimal clinical trial settings, the median overall survival after curative resection ranges from 20 to 28 months. 4
Recurrence is common: 80‑85 % of patients who undergo resection develop disease recurrence, most often early hepatic metastases. 5

Achieving an R0 (margin‑negative) resection is the strongest independent predictor of long‑term survival. 3
A lymph‑node ratio (LNR) ≥ 0.2 independently predicts poorer outcomes. 3

Pre‑treatment serum CA 19‑9 levels ≥ 110‑230 U/mL are associated with significantly worse prognosis. 6
Elevated CA 19‑9 after resection correlates with inferior survival. 3

Age ≥ 70 years independently predicts reduced survival. 6
An ECOG performance status of 0‑1 is required to tolerate intensive therapeutic regimens. 7

Avoid non‑curative resections when tumor infiltration involves the celiac axis or superior mesenteric artery, as R0 resection is rarely achievable in these scenarios. 3
Perform accurate staging with multiphase CT to prevent unnecessary, high‑morbidity surgeries that are unlikely to provide benefit. 5

In patients with metastatic (stage IV) poorly differentiated pancreatic adenocarcinoma, the 5‑year overall survival is approximately 2 %【8】【9】.
For the same population, the 1‑year overall survival is about 15 %【10】.

A lymph‑node ratio (LNR) ≥ 0.2 independently predicts poorer outcomes after resection of poorly differentiated tumors【11】.
Achieving an R0 (margin‑negative) resection is the strongest pathological predictor of long‑term survival in this cohort【11】.

Patients must have an ECOG performance status of 0–1 to be eligible for intensive chemotherapy regimens (e.g., FOLFIRINOX)【8】【9】.
When planning neoadjuvant therapy, a pre‑treatment biopsy confirming the differentiation grade (G3) is essential to ensure appropriate therapeutic selection【12】.

Second‑line after progression on FOLFIRINOX: gemcitabine combined with nab‑paclitaxel is recommended【8】【9】.
Second‑line after progression on gemcitabine‑based therapy: fluorouracil plus nanoliposomal irinotecan is recommended【8】【9】.
For patients with ECOG PS 2 or significant comorbidities: single‑agent gemcitabine or fluorouracil is advised as a less intensive option【8】【9】.